New boron-based compounds for the treatment of alzheimer's disease

Boron-based compounds combined with low-energy neutron irradiation provide a selective treatment for Alzheimer's disease by targeting amyloid beta aggregates, enhancing the effectiveness of amyloid beta treatments while minimizing damage to healthy brain tissue.

WO2024231837A1PCT designated stage expired Publication Date: 2024-11-14UNIV DEGLI STUDI DI TORINO +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054446
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-07
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for Alzheimer's disease lack selectivity and effectiveness in targeting amyloid beta peptide aggregates, leading to significant side effects and limited improvement in cognitive function, with existing radiotherapies not being specific enough to prevent damage to healthy brain tissue.

Method used

Development of boron-based compounds that, when combined with low-energy neutron irradiation, selectively interact with and damage amyloid beta protein aggregates through Capture-Enhanced Neutron Irradiation (CENI), utilizing boron and gadolinium derivatives to enhance the neutron capture process and create a targeted radiation field within the brain.

Benefits of technology

This approach allows for selective and localized treatment of amyloid beta aggregates, reducing neuroinflammation and clearing plaques, thereby improving memory processing and synaptic function with reduced harm to healthy brain tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2024054446_14112024_PF_FP_ABST
    Figure IB2024054446_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to new boron-based compounds for the treatment of Alzheimer's disease by irradiation with neutrons amplified by neutron capture reactions (Capture-Enhanced Neutron Irradiation, CENI), and the relative preparation methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] “NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE”

[0002] The present invention relates to new boron-based compounds for the treatment of Alzheimer's disease by irradiation with neutrons amplified by neutron-captre reactions (Capture-Enhanced Neutron Irradiation (CENI)), relative synthesis methods and pharmaceutical formulations.

[0003] BACKGROUND OF THE INVENTION

[0004] Alzheimer's disease (AD), the most common cause of dementia, in addition to resulting in significant economic costs, has an enormous impact on the quality of life of patients, their families and their caregivers.

[0005] 46.8 million people live with Alzheimer's disease worldwide and the number of people affected by the disorder is expected to double every 20 years in the future.

[0006] There is currently no cure for Alzheimer's disease, and only one new drug has been approved by the FDA since 2002. The current strategy involves a combination of pharmacological and non-pharmacological treatments with the aim of attenuating the progressive loss of cognitive and functional abilities, trying to partially improve the compromised brain functions, without acting in any way on the causes.

[0007] Most treatments that modify or slow down the course of the disease focus on the breakdown of the amyloid beta (AP) peptide, exploiting the drug-mediated targeting of the amyloidogenic and non-amyloidogenic pathways [1],

[0008] In July 2019, the Alzheimer's Disease International (ADI) website reported that Novartis, Amgen, and the Banner Alzheimer's Institute had discontinued two II / III phase studies of a new drug due to serious side-effects associated with insignificant improvements. in the cognitive function and behaviour [cfir. https: / / www.alz.co.uk / news / novartis-amgen-and-banner-alzheimers-institute- remain-committed-after-discontinuation].

[0009] At the same time, innovative strategies have been tested that explore other routes and approaches, such as low-dose LD-RT radiotherapy [2] even if the latter does not prove to be specific for this type of disease. All radiotherapies proposed so far are not selective enough to prevent damage to healthy brain tissue.

[0010] The need is therefore evident for an effective treatment of Alzheimer's disease (AD) that is capable of selectively interacting with the proteins of the Ap amyloid beta peptide aggregates independently of the gene expression and bio- molecular processes leading to overexpression of the Ap protein.

[0011] DESCRIPTION OF THE INVENTION

[0012] The authors of the present invention have now developed a completely new and alternative strategy for the treatment of Alzheimer's disease which is based on a “physical attack” limited to Ap aggregates. The treatment proposed is based on the synergistic action of two agents, namely i) low-energy neutrons, and ii) binders containing10B (boron) and optionally also157Gd (gadolinium) capable of selectively interacting with Ap proteins to produce structural and targeted damage to the aggregates themselves. Both agents are inert when administered alone. To be effective, this strategy requires the Capture -Enhanced Neutron Irradiation (CENI) technique of the Ap aggregates.

[0013] In particular, the invention exploits the synergy between an external beam of low-energy neutrons, with which the whole brain is irradiated, and molecules specifically derivatized to increase the final effect (called CENI agents). After the accumulation of the CENI agent in the Ap aggregates, irradiation with a neutron beam will in fact produce a localized increase in the dose administered exclusively within the Ap aggregate itself. These molecules which play the role of amplifiers of the damage induced by ionizing radiation will be capable of crossing the blood-brain barrier (BBB) and selectively bind to Ap, whereas the enhancement effect will derive from157Gd and10B or nuclides capable of capturing the neutrons with which the CENI agent is derivatized.

[0014] The nuclear reactions induced by low-energy neutrons are as follows:

[0015] •10B + n -> a +7Li (R < 10 pm) plus a 478 keV induced X-ray (about 94%).

[0016] •157Gd + n -> (158Gd)*, leading to induced X-rays (about 31%) or Internal Electron Conversion (69%) followed by Auger electrons (ranges, R, from a few to hundreds of nm) and characteristic X-rays. In this way, in correspondence with the Ap aggregates, a mixed radiation field (low + high) is created by linear energy transfer (LET) which allows a bimodal treatment:

[0017] (1) selective irradiation by charged secondary particles (secondaries) charged with a high biological effect; and

[0018] (2) a long-distance stimulation of brain tissue by penetrating photons.

[0019] Without intending to be bound to any theory, the use of the compounds according to the invention for the treatment proposed by eliminating a source of oligomers, will produce the clearance of the plaques, and consequently reduce the extent of neuroinflammation. Furthermore, the main disturbing elements for synapses and memory processing will be removed (Figure 1).

[0020] The10B neutron capture therapy (called Boron Neutron Capture Therapy, BNCT) has already been exploited in clinical treatments as a non-invasive therapy for the local treatment of invasive malignancies and successfully applied to primary brain tumours and recurrent tumours of the head and neck.

[0021] The potential high selectivity of the mechanism on which BNCT is based makes it a powerful option for the treatment of diffuse metastases and infiltrated tumours, whose treatment cannot be addressed with methods that require precise localization of the tumour mass such as an operation or conventional radiotherapy.

[0022] WO2020 / 252439 Al for example describes hydroxamic acid derivatives having a carborane function directed at metalloproteinases of the matrix for use in the10B neutron capture therapy (BNCT) for the treatment of tumours and rheumatoid arthritis.

[0023] The present invention therefore relates to compounds having formula (I):

[0024] R1-R2-X-R3-Z-R4 (I) wherein:

[0025] X is a closo- or nido-ortho (a cluster of atoms containing nine or ten boron atoms) containing boron atoms either in natural abundance or enriched in10B ornB as illustrated hereunder: X: X: c / o o-carborane w b-carborane

[0026] O =10BH,11BH * = C M+: Na+, K+, Cs+

[0027] O =10BH,11BH « = C

[0028] Ri, present only if R2 is different from a hydrogen atom, is a macrocycle selected from the group which consists of:

[0029] - l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA),155Gd-DOTA,157Gd-DOTA;

[0030] - diethylenetriaminepentaacetic acid (DTP A),155Gd-DTPA,157Gd-DTPA;

[0031] - 1,4,7- triazacyclononane-l,4,7-triacetic acid (NOTA),155Gd-NOTA,157Gd- NOTA;

[0032] - tetraazacyclodidecane-BN, N', N", N'" tetra methylenephosphonate (DOPT),155Gd-DOTP,157Gd-DOTP;

[0033] R2 is a hydrogen atom or, if Ri is present, it is a C2-C12 alkyl or heteroalkyl chain optionally comprising one or more functional groups selected from a triazole ring, amide group, urea or thiourea;

[0034] R3 is an alkyl chain having the formula Cx-Y-Czwherein:

[0035] Cxis a C2-C6 alkyl chain;

[0036] Y is a triazole ring, or an amide group, urea or thiourea

[0037] Czis a -(CH2)n- group, wherein n is an integer ranging from 2 to 6, -CH2NH-, -(CH2O)m-, -(CH2CH2O)m-, -(CH2CH2O)mCH2- wherein m is an integer ranging from 1 to 3;

[0038] Z is an oxygen, sulfur or NH group;

[0039] R4 is selected from the group which consists of: wherein Q is -CH- or -N-; wherein Rs and Re, the same as or different from each other, are selected from the group which consists of:

[0040] - an aromatic ring containing from one to three substituents having the following formula: wherein G, G’, G”, the same as or different from each other, can be selected from the group consisting of H, OH, Ci-Ce linear alkyloxy or halogen (F, I, Cl and Br); or R4 can be:

[0041] - an aromatic ring containing a heteroatom selected from the group consisting of: 2-pyridyl, 3-pyridyl or 4-pyridyl, benzoxazole, or benzothiazole or stilbene derivatives selected from the group consisting of: wherein the groups R7 and Rs, the same as or different from each other, are a Ci- C , linear alkyl group; stereoisomers thereof or pharmaceutically acceptable salts thereof with alkaline metals.

[0042] The compounds of the invention that contain ni do-carb orane should be considered in mono-anionic form. Nido-carborane is intended as being a mixture of stereoisomers in all its ratios.

[0043] The nido-carborane counterion M+can be selected from one of the following alkaline metal cations Na+, K+, Cs+.

[0044] Closo- or nido- ortho carborane (X in formula (I)) is a binder capable of interacting selectively with Ap aggregates. In a particular embodiment the closo- or nodo-ortho carborane contains a further functionalization (Ri according to general formula (I)) with a complex containing Gd. The macrocycle (Ri) is in fact a group capable of coordinating gadolinium or which coordinates gadolinium.

[0045] Gd can be exploited not only for increasing the neutron capture process, but also as a contrast agent for diagnostic imaging (MRI) capable of providing information on the biodistribution and therefore on the concentration of B and Gd.

[0046] Probes containing Gd, in fact, allow the in vivo quantification of the capture agent accumulated in the Ap aggregate, via MRI, immediately before irradiation with neutrons. The biodistribution images of the capture agent via MRI will allow the personalization of irradiation and dosimetry of each treatment with respect to the quantity of drug accumulated in each individual patient.

[0047] According to a preferred embodiment of the present invention the group R4 of the compounds having formula (I) comprises a monocarbonyl analogue of curcumin (MAC). The general structural formula of MACs is shown in Figure 2 on the left. MACs are analogues of curcumin that have demonstrated biological activity comparable to the latter, together with greater stability in vivo [3], The present invention relates to the compound having formula (21)

[0048] (indicated as Phoenix):

[0049] Phoenix

[0050] According to a further preferred embodiment of the present invention, the group R4 in the compounds having formula (I) according to the invention comprises a derivative of benzothiazole, benzoxazole or stilbene, i.e. molecules which have demonstrated good permeability of the blood-brain barrier and high affinity for amyloid Ap aggregates.

[0051] In a preferred embodiment of the compounds having formula (I) according to the present invention, said benzothiazole derivatives are selected from:

[0052] According to a preferred alternative embodiment of the compounds having formula (I) of the present invention, said stilbene derivatives are selected from the group consisting of:

[0053] wherein the groups R7 and Rs, the same as or different from each other, are a Ci- Cl, linear alkyl group.

[0054] Among these, the compound Pittsburgh B and Florbetaben have proven to be particularly advantageous (whose derivatives labelled as 11C and 18F have been used as PET probes similar to amyloid plaques and are currently being studied in the clinical phase) whose formulas are shown in Figure 2 .

[0055] The present invention also relates to the compound having formula (24) (indicated as BPiB):

[0056] • = C

[0057] O = BH BPiB

[0058] The present invention further relates to the compound having formula (11) (indicated as B -florbetaben):

[0059] • = C O = BH B-Florbetaben

[0060] The present invention is also directed towards compounds having formula (I) according to the invention for use in the treatment of Alzheimer's disease. Said compounds are preferably the compounds having formula (21), (24) and (11) described above.

[0061] The present invention also relates to the compounds according to the invention for use in the treatment of Alzheimer's disease by Neutron Irradiation Enhanced by Capture Reactions (CENI).

[0062] The invention is also directed towards compounds according to the invention, when comprising Gadolinium, for use as probes in diagnostic methods based on imaging techniques, preferably MRI.

[0063] The invention further relates to pharmaceutical compositions comprising one of the compounds according to the invention as an active ingredient together with one or more pharmacologically acceptable excipients and / or adjuvants.

[0064] The present invention also relates to a nanoformulation comprising the compounds having formula (I) according to the invention as active ingredient. The compounds according to the invention can in fact be administered in the form of nanoformulations capable of increasing the passage through the blood-brain barrier and at the same time incorporating and conveying highly lipophilic and insoluble molecules in an aqueous environment. The blood-brain barrier is a highly selective barrier that separates blood from the brain and prevents many molecules from entering the brain tissue. The nanoformulations can be administered intravenously, intraperitoneally or subcutaneously.

[0065] Said nanoformulation preferably comprises: i) co-glycolic lactic acid (PLGA) polymer nanoparticles; ii) cyclodextrins in monomeric or polymeric form; iii) apoferritin; in combination with at least one of the compounds having formula (I). Said compound is preferably selected from the compounds having formula (24), (11) or (21) described above.

[0066] In a preferred embodiment of the present invention said compound present in nanoformulations is compound (21).

[0067] PLGA nanoparticles are biodegradable and biocompatible polymer-based particles that have been extensively studied for various biomedical applications. PLGA nanoparticles can be surface modified with PEG (polyethylene glycol) to improve their biocompatibility, stability and circulation time in vivo. It has been demonstrated that PEGylation of PLGA nanoparticles improves their pharmacokinetics and biodistribution, reducing their clearance by the reticuloendothelial system and increasing their circulation time in the bloodstream. Furthermore, PEGylation can reduce the immune response to nanoparticles, as well as reduce protein adsorption and opsonization, resulting in improved biocompatibility and reduced toxicity. This is particularly important for the development of nanoparticle-based drug delivery systems for clinical use. The PLGA nanoparticles preferably comprise the compound having formula (21) according to the invention.

[0068] Cyclodextrins (CDs) are cyclic oligosaccharides consisting of 6,7,8 glucopyranose units linked together to form a-, P- and y-cyclodextrins respectively. Cyclodextrins form a lipophilic central cavity having a hydrophilic outer surface.

[0069] Hydrophilic drug / cyclodextrin complexes are formed through the inclusion of a lipophilic drug or a portion thereof into the central cavity of the cyclodextrin. The lipophilic cavity hosts the lipophilic molecules, whereas the external polar surface of the CD molecule allows them to be transported into the aqueous environment. The formation of the supramolecular adduct with P-CD significantly improves the solubility of the compounds according to the invention in an aqueous environment. Carboranes have in fact shown a high affinity for P-CDs. Furthermore, commercially available high-molecular-weight cyclodextrin polymers can also be advantageously used. The high molecular weight of P-CD polymers (from 100 to 600 KDa) should favour a prolonged release of the encapsulated molecules compared to the use of the single P-CD monomer.

[0070] Apoferritin is a natural protein that can be used as a nano-carrier thanks to its ability of self-assembly into a highly stable symmetrical structure. Apoferritin is composed of 24 subunits that form a hollow spherical structure with a diameter of approximately 12-13 nm. The internal cavity can be used for encapsulating various molecules such as drugs, peptides, nucleic acids and imaging agents. Apoferritin has various advantages with respect to other types of nano-carriers. The high stability and biocompatibility, for example, make apoferritin an ideal candidate for drug delivery. H-apoferritin can preferably be used as a carrier for the compounds according to the invention which would otherwise not be able to cross the blood-brain barrier.

[0071] The present invention also contemplates a process for the synthesis of the compound having formula (21) comprising the following steps: i) Claisen-Schmidt condensation between 4-hydroxycyclohexan-l-one (16) and 3,4-bis((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (17) to obtain 2,6-Bis((E)-3,4-bis((tetrahydro-2H-pyran-2-yl)oxy)-benzyl- idene)-4-hydroxycyclohexan-l-one (18); ii) propargylation reaction of compound (18) with propargyl bromide to obtain 2,6-bis((E)-3,4-bis((tetrahydro-2H-pyran-2-yl)oxy) benzyl- idene)-4-( prop-2-in-l-yloxy)cyclohexan-l-one (19); iii) Huisgen reaction of compound (19) with 2-(C-o-carboranyl)-l- azidoethane to obtain compound (20); iv) deprotection of compound (20) in an acidic environment to obtain compound (21).

[0072] The present invention also relates to a process for the synthesis of the compound having formula (11) comprising the following steps:

[0073] (i) monopropargylation of triethylene glycol (2) with propargyl bromide (1) to obtain 2-(2-(2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethane- 1 -ol (3);

[0074] (ii) tosylation of compound (3) to obtain 2-(2-(2-(prop-2-in-l- yloxy)ethoxy)ethoxy)ethyl 4-toluene sulfonate (4);

[0075] (iii) Williamson etherification of 4-hydroxy benzaldehyde (5) to obtain 4-(2-(2- (2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethoxy)benzaldehyde (6);

[0076] (iv) Horner-Wadsworth -Emmons reaction of compound (6) for the synthesis of stilbene (E)-l-nitro-4-(4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)- styryl)benzene (8);

[0077] (v) reduction of the nitro group of compound (8) to obtain (E)-4-(4-(2-(2-(2- (prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline ( 9); (vi) reductive amination of compound (9) to obtain (E)-N-methyl-4-(4-(2-(2-(2- (prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline (10);

[0078] (vii) Huisgen reaction of compound (10) with 1-C-ortho-carboranylethanazide to obtain compound (11).

[0079] Finally, the present invention relates to a process for the synthesis of the compound having formula (24) comprising the following steps: i) propargylation reaction of the compound 4-(6-methoxybenzo[d]thiazol-2- yl)aniline (22) by addition of propargyl bromide to obtain 4-(6- methoxybenzo[d]thiazol-2-yl)-N-( prop-2-in-l-yl) aniline (23); ii) Huisgen reaction of the compound 4-(6-methoxybenzo[d]thiazol-2-yl)-N- (prop-2-in-l-yl) aniline (23) with 1-C-ortho-carboranylethanazide to obtain the compound (24).

[0080] The present invention will now be described for illustrative but nonlimiting purposes, according to a preferred embodiment with particular reference to the attached figures, in which:

[0081] - Figure 1 shows the mechanism of action proposed for the action of BNCT on Ap plaques;

[0082] - Figure 2 shows the formulas of the MAC compound (left), the Pittsburg B compound (centre) and the Florbetaben compound (right);

[0083] - Figure 3 shows the structure of the preferred compounds synthesized according to the present invention, i.e. containing a carboranic unit derivatized with MACs (Phoenix, left), the compound Pittsburgh B (BPiB, right) and the drug Florbetaben© (bottom);

[0084] - Figure 4 shows the graph with the fluorescence measurements of samples containing 100 nM thioflavin (ThT) and variable quantities of Ap fibrils;

[0085] - Figure 5 shows the competition assays using the ThT probe, measuring the fluorescence emission to determine the affinity for Ap fibrils;

[0086] - Figure 6 shows the results of the ICP-MS analysis of the boron content effected ex vivo 24 hours after the administration of PLGA-Phoenix in the brain of mice treated with vehicle and PLGA-Phoenix (SQ = subcutaneous injection; IV = intravenous injection); - Figure 7 shows FESEM images of Ap fibrils deposited on gold-metallized slides;

[0087] - Figure 8 shows the % reduction of Ap fibril aggregates irradiated for 1 hour at 250 Kw in the presence of the compound Phoenix (21) or not irradiated.

[0088] - Figure 9 shows the ThT-induced fluorescence of the Ap samples before and after irradiation at 250Kw (1 hour grey column, 15 minutes white column).

[0089] - Figure 10 shows the representative analysis of FESEM images of an Ap CTRL and an Ap treated with Phoenix (21) both irradiated at 250 Kw for 1 hour.

[0090] - Figure 11 (top graph) shows the optical densities measured on FESEM images normalized with respect to the non-irradiated CTRL. The black, dark grey, light grey and white bars correspond respectively to: control Ap fibrils, Phoenix-treated Ap fibrils, Chimera-treated Ap fibrils, BPiB-treated Ap fibrils. The dashed bars correspond to the irradiated samples (250 kW, Ih). Bottom: Representative FESEM images of the different non-irradiated (NNIRR) and irradiated (250 kW, Ih) samples.

[0091] - Figure 12 shows the results of irradiation with non-mature proto-fibrils.

[0092] - Figure 13 shows the results relating to the quantification of the signal intensity of Ap fibrils irradiated under different conditions. Panel A) Quantification of the signal intensity of Ap fibrils irradiated for 15 minutes at 250kW reactor power. Panel B) Quantification of the signal intensity of Ap fibrils irradiated for 15 minutes at 30kW reactor power.

[0093] - Figure 14 shows the SPR (Surface Plasmon Resonance) signal and the dependence on the quantity of oligomers.

[0094] The following illustrative, but not limiting, examples of the invention are provided for a better illustration of the invention,.

[0095] EXAMPLES

[0096] EXAMPLE 1 : Synthesis of the compounds according to the invention

[0097] Synthesis of carboranylflorbetaben (11)

[0098] The synthesis scheme of carboranylflorbetaben or B-Florbetaben (11) is illustrated in the following scheme:

[0099]

[0100] Monopropargylation of triethylene glycol (2): synthesis of 2-(2-(2-(prop-2-in-l- yloxy)ethoxy)ethoxy)ethan-l-ol (3)

[0101] Triethylene glycol (2) (13.35 ml, 100 mmoles, 5 equ.) and 4 ml of H2O are added to a 50 ml flask with a magnetic stir bar. The solution is cooled to 0°C, followed by the addition of KOH (2.24 g, 40 mmoles, 2 equ.) and propargyl bromide (1) (1.78 ml, 20 mmoles, 1 equ; 80% sol in toluene w / w). The reaction mixture is stirred vigorously for 17 hours at room temperature, monitoring the conversion by means of TLC (EP:AcOEt 70:30). H2O is added, extracted with DCM (3 x 15 ml), the organic phase is washed with brine (4 x 20 ml), dried with Na2SO4 and the solvent is evaporated at reduced pressure. 2-(2-(2-(prop-2-in-l- yloxy)ethoxy)ethoxy)ethan-l-ol (3) (2.71 g, 14 mmoles, 72%) is obtained as an orange liquid

[0004] 'H-NMR 8 (600MHz, CDCh): 4.20 (d, 2H, J= 3.8 Hz, O-CH2-C=); 3.73-3.65 (m, 10H, O-CH2-CH2-O); 3.61-3.60 (m, 2H, CH2-OH); 2.42 (t, 1H, J = 2.4 Hz, C=CH); 1.80-1.50 (sa, 1H, OH).

[0102] Tosylation of 2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethan-l-ol (3): synthesis of 2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethyl 4-toluenesulfonate (4)

[0103] 2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethan-l-ol (3) (0.80 g, 4.2 mmoles, 1 equ.), DMAP (0.52 g, 4.2 mmoles, 1 equ.) and iPr2NEt (0.79 ml, 4.6 mmoles, 1.1 equ.) in 40 ml of anhydrous DCM, are dissolved under N2 in a 100 ml flask with a magnetic stir bar previously flamed under vacuum. The solution is brought to 0°C and TsCl (0.87 g, 4.6 mmoles, 1.1 equ.) is subsequently added. The solution is stirred at 0°C for 1 hour. After returning to room temperature, it is left under stirring for a further 30 minutes. The conversion is then monitored with TLC (EP:AcOEt 50:50). The reaction mixture is subsequently quenched with 0.1N HC1 (45 ml) and extracted with DCM. The organic phase is washed with brine (1 x 40 ml) and anhydrified with Na2SO4. The solvent is evaporated under reduced pressure and a yellow oil is obtained. The raw product is purified by means of a chromatographic column (stationary phase / grams of raw product: 20 / 1, silica deactivated with 1% Et3N; eluent EP:AcOEt 50:50; Rf = 0.40). 2-(2- (2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethyl 4-toluenesulfonate (4) (1.29 g, 3.8 mmoles), is obtained as a yellow oil, with 89% of yield [5],

[0104] 'H-NMR 8 (600MHz, CDCh): 7.79 (dm, 2H, J= 8.5 Hz, Ar-H); 7.33 (dm, 2H J= 8.5 Hz, Ar-H); 4.18 (d, 2H, J = 2.4 Hz, O-CH2-C=); 4.14-4.16 (m, 2H, SO2-O- CH2); 3.69-3.66 (m, 4H, O-CH2-CH2-O); 3.64-3.62 (m, 2H, O-CH2); 3.58 (s, 4H, O-CH2-CH2-O); 2.43 (s, 3H, Ar-C-CH3); 2.41 (t, 1H, J= 2.4 Hz, C=CH). Williamson etherification of 4-hydroxybenzaldehyde (5): synthesis of 4-(2-(2-(2- (prop-2-in-l -yloxy)ethoxy)ethoxy)ethoxy)benzaldehyde (6)

[0105] 2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethyl 4-toluene sulfonate (4) (2.02 g, 5.8 mmoles, 1.1 equ.), 4-hydroxybenzaldehyde (5) (0.65 g, 5.3 mmoles, 1 equ.) and K2CO3 (2.42 g, 17.5 mmoles, 3 equ.) in 40 ml of DMF are dissolved in a 100 ml flask with a magnetic stir bar previously flamed under vacuum. The mixture is heated to 100°C overnight. Once complete conversion has taken place (TLC, EP:AcOEt 60:40), the reaction mixture is filtered and the filtrate concentrated under reduced pressure. The oil obtained is diluted in DCM and the organic phase is washed with brine (7 x 10 ml) to remove the DMF. It is dried with Na2SO4 and the solvent is evaporated under reduced pressure. The raw product is purified by means of a chromatographic column (stationary phase / grams of raw product: 20 / 1, silica deactivated with 1% EtiN; eluent EP:AcOEt 60:40; Rf = 0.26). 4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy) ethoxy)ethoxy)benzaldehyde (6) (1.39 g, 4.8 mmoles) is obtained as an almost colourless viscous oil, with 90% yield [6],

[0106] 'H-NMR 8 (600MHz, CDCh): 9.87 (s, 1H, HC=O); 7.82 (dm, 2H, J = 8.8 Hz, Ar-H); 7.01 (dm, 2H, J = 8.8 Hz, Ar-H); 4.22-4.20 (m, 2H, Ar-O-CH2); 4.19 (d, 2H, J = 2.5 Hz, O-CH2-C=); 3.89-3.88 (m, 2H, O-CH2); 3.74-3.72 (m, 2H, O- CH2); 3.70-3.67 (m, 6H, O-CH2-CH2-O); 2.41 (t, 1H, J= 2.4 Hz, C=CH).

[0107] Homer-Wadsworth-Emmons reaction synthesis of stilbene (E)-l-nitro-4-(4-(2-(2- (2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethoxy)styryl)benzene (8)

[0108] 4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)benzaldehyde(6), (0.98 g, 3.4 mmoles, 1 equ) in 5 ml of anhydrous THF, are dissolved in a 25 ml flask with a magnetic stir bar previously flamed under vacuum, under N2. NaH (0.09 g, 3.7 mmoles, 1.1 equ.) and diethyl (4-nitrobenzyl)phosphonate (7) (1.37 g, 5.0 mmoles, 1.5 equ.) are subsequently added, at -10°C. The mixture is mixed at this temperature for 20 minutes, and then at room temperature for 3 hours. The conversion is monitored with TLC (EP:AcOEt50:50). The reaction is quenched with 10 ml of H2O, extracted with AcOEt (3 x 15 ml) and the organic phase is washed with brine (3 x 15 ml). It is dried with Na2SO4 and the solvent is evaporated under reduced pressure. The raw product is purified by means of a chromatographic column (stationary phase / grams of raw product: 50 / 1, silica deactivated with 1% EtsN; eluent DCM:MeOH 400:1; Rf = 0.25). Stilbene (E)-l- nitro-4-(4-(2-(2-(2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethoxy)styryl)benzene is obtained (8), as a yellow solid, (0.80 g, 1.9 mmoles) with a yield of 58% [7], Reduction of the nitro group of (E)-l-nitro-4-(4-(2-(2-(2-(prop-2-in-l- yloxy)ethoxy)ethoxy)ethoxy)styryl) benzene (8): synthesis of (E)-4-(4-(2-(2-(2- (prop-2-in-l -yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline (9)

[0109] SnCl2*2H2O (1.41 g, 5.5 mmoles, 5 equ.) is dissolved in 20 ml of EtOH in a 50 ml flask with a magnetic stir bar, followed by 1 equ. of (E)-l-nitro-4-(4-(2-(2- (2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)-styryl) benzene (8) (0.45 g, 1.1 mmoles). The solution is reflux heated for 4 hours. The reaction is monitored with TLC (EP:AcOEt50:50) until conversion takes place. The solvent is well evaporated under reduced pressure and extracted with AcOEt. The organic phase is washed with brine and, subsequently, with IM NaOH (3 x 10 ml) and then with NaHCCh (1 x 10 ml) to neutralize the anilinium ion. The solution changes from red to yellow. It is dried with Na2SO4 and the solvent is evaporated under reduced pressure. (E)-4-(4-(2-(2-(2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethoxy)styryl)- aniline (9) (0.42 g, 1.1 mmoles) is obtained as a yellow-orange waxy solid, with a quantitative yield [8], 'H-NMR 8 (600MHz, CDCh): 7.37 (dm, 2H, J = 8.8 Hz, Ar-H); 7.29 (dm, 2H, J = 8.5 Hz, Ar-H); 6.89-6.86 (m, 4H, Ar-H e Ar-CH=CH-Ar); 6.66 (dm, 2H, J= 8.4 Hz, Ar-H); 4.19 (d, 2H, J = 2.4 Hz, OCH2C=); 4.14-4.12 (m, 2H, Ar-O-CH2); 3.86-3.84 (m, 2H, O-CH2); 3.74-3.72 (m, 2H, O-CH2); 3.70-3.67 (m, 6H, O-CH2- CH2-O); 2.41 (t, 1H, J= 2.4 Hz, C=CH).

[0110] 13C-NMR 8 (150MHz, CDCh): 158.1 (Cq); 145.7 (Cq); 131.0 (Cq); 128.6 (Cq); 127.5 (2 x CH); 127.3 (2 x CH); 126.8 (2 x CH); 124.8 (2 x CH); 115.4 (CH); 114.9 (CH); 77.3 (CH); 74.6 (Cq); 70.9 (CH2); 70.8 (CH2); 70.6 (CH2); 69.9 (CH2); 69.2 (CH2); 67.6 (CH2); 58.5 (CH2).

[0111] IR: 3361 and 3258 cm'1(weak intensity, N-H stretching and C-H alkyne stretching); 2921 and 2869 cm'1(weak intensity, C-H stretching); 2113 cm'1(very weak intensity, C=C stretching); 1602 cm'1(medium intensity, C=C stretching); 1093 cm'1(strong intensity, C-0 stretching); 830 cm'1(strong intensity, C-H bending para-substituted aromatic ring). Reductive amination of (E)-4-(4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy)- ethoxy)ethoxy)styryl)aniline (9): synthesis of (E) -N-methyl-4-(4-(2-(2-(2-(prop- 2 -in- 1 -yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline (10)

[0112] (E)-4-(4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline

[0113] (9) (0.41 g, 1.1 mmoles, 1 equ.), paraformaldehyde (0.19 g, 6.4 mmoles, 6 equ.) and 6 equ. of NaOMe (0.35 g, 6.4 mmoles) in 25 ml of MeOH, are dissolved in a 50 ml flask with a magnetic stir bar (9). The solution is reflux heated for 2 hours. The solution is brought to 0°C and NaBH4 (0.24 g, 6.4 mmol, 6 equ.) is added. The solution is subsequently heated to reflux for 1 hour and monitored with TLC (DCM:MeOH 200: 1) until conversion takes place. The solvent is evaporated under reduced pressure and extracted with a 50:50 solution of AcOEt:H2O (3 x 10 ml). The organic phase is washed with brine until the solution becomes transparent, it is dried with Na2SO4 and the solvent is evaporated under reduced pressure, obtaining a yellow-orange oil. The raw product is purified by means of a chromatographic column (stationary phase / grams of raw product: 100 / 1, silica deactivated with 1% Et3N; eluent DCM:MeOH 200: 1; Rf = 0.22). (E)-N-methyl-4-(4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)- niline (10) is obtained (0.16 g, 0.4 mmoles, 37%), as a yellow ochre solid [9], 'H-NMR 8 (600MHz, CDCh): 7.38 (dm, 2H, J = 8.7 Hz, Ar-H); 7.34 (dm, 2H, J = 8.6 Hz, Ar-H); 6.90-6.83 (m, 4H, Ar-H e Ar-CH=CH-Ar); 6.63 (dm, 2H, J= 8.4 Hz, Ar-H); 4.19 (d, 2H, J = 2.4 Hz, O-CH2-C=); 4.14-4.12 (m, 2H, Ar-O-CH2); 3.86-3.84 (m, 2H, O-CH2); 3.74-3.72 (m, 2H, O-CH2); 3.70-3.67 (m, 6H, O-CH2- CH2-O); 2.86 (s, 3H, NH-CH3); 2.41 (t, 1H, J= 2.4 Hz, C=CH).

[0114] °C-NMR 8 (150MHz, CDCh): 158.0 (Cq); 148.8 (Cq); 131.2 (Cq); 127.5 (2 x CH); 127.21 (2 x CH); 127.17 (Cq); 127.05 (2 x CH); 124.1 (2 x CH); 114.9 (CH); 112.6 (CH); 79.8 (Cq); 74.6 (CH); 70.9 (CH2); 70.8 (CH2); 70.6 (CH2); 69.9 (CH2); 69.2 (CH2); 67.6 (CH2); 58.5 (CH2); 30.8 (CH3).

[0115] IR: 3404 and 3223 cm'1(weak intensity, N-H stretching and C-H alkyne stretching); 2908 and 2870 cm'1(medium intensity, C-H stretching); 1606 cm'1(strong intensity, C=C stretching); 1091 cm'1(strong intensity, C-0 stretching); 829 cm'1(strong intensity, C-H bending para-substituted aromatic ring). m.p. = 95-99°C

[0116] Tosylation of 1-butynol (12): synthesis of but-3-in-l-yl 4-toluenesulfonate (13)

[0117] 1 equ. of 1-butynol (12) (0.50 ml, 6.6 mmoles) in 7.5 ml of anhydrous THF is diluted, under N2, in a 50 ml Schlenk vial equipped with a magnetic stir bar flamed twice under vacuum. The solution is brought to -78°C and 1.1 equ. of n- butyl lithium (2.80 ml, 7.3 mmoles) is added dropwise. After 5 minutes, the solution is brought to 0°C and stirred for 30 minutes. A solution of tosyl chloride (1.51 g, 7.9 mmoles, 1.2 equ.) in 8 ml of anhydrous THF is subsequently added to the reaction mixture, which is stirred for a further 30 minutes at 0°C. Once the conversion has taken place, 2 ml of H2O are added to quench the reaction, the THF is evaporated and extracted with Et2O (3 x 10 ml). It is dried with Na2SO4 and the solvent is evaporated under reduced pressure obtaining a yellowish oil. The raw product is purified by means of a chromatographic column (stationary phase / grams of raw product: 20 / 1, silica deactivated with 1% Et3N; eluent EP:AcOEt 90:10; Rf = 0.27). But-3-in-l-yl 4-toluenesulfonate (13) (1.01 g, 4.5 mmoles) is obtained as a transparent liquid, with a yield of 68%

[0010] , 'H-NMR 8 (600MHz, CDCh): 7.80 (dm, 2H, J= 8.4 Hz, Ar-H); 7.34 (dm, 2H J= 8.6 Hz, Ar-H); 4.09 (t, 2H, J= 7.1 Hz, O-CH2); 2.55 (td, 2H, Ji = 7.1 Hz, Ji = 2.7 Hz, CH2-C=); 2.44 (s, 3H, Ar-CH3); 1.96 (t, 1H, J= 2.7 Hz, C=CH).

[0118] Insertion of decaborane on the alkyne but-3-in-l-yl 4-toluenesulfonate (13): synthesis of l-C-ortho-carboranyl-2-(4-toluenesulfonate)ethane (14) l-butyl-3-methylimidazolium chloride (0.130 g, 0.7 mmoles, 0.7 equ.) is added under N2, in a vial with a magnetic stir bar previously flamed twice under vacuum. The vial is flamed twice more and left under vacuum for 1 hour, heating to 90°C. The solution is subsequently cooled and passed under N2. B10H14 (0.122 g, 1.0 mmoles, 1 equ.) and but-3-in-l-yl 4-toluenesulfonate (13) (0.336 g, 1.5 mmoles, 1.5 equ.) are then added.. The solution is left under vacuum for 5 minutes (the solution releases hydrogen) and 2.5 ml of anhydrous toluene are then added. The reaction mixture is reacted at 120°C for 2 hours. The conversion is monitored with TLC (EP:AcOEt 70:30). The toluene is evaporated and a yellow oil is obtained. The raw product is purified by means of a chromatographic column (stationary phase 30 g of SiO2deactivated with 1% Et3N; eluent EP:AcOEt 85: 15; Rf = 0.33). l-C-ortho-carboranyl-2-(4-toluenesulfonate)ethane (14) (0.102 g, 0.3 mmoles, 30%) is obtained as a white solid

[0011] ,

[0119] 'H-NMR 8 (600MHz, CDCh): 7.77 (dm, 2H, J = 8.3 Hz, Ar-H); 7.38 (dm, 2H, J = 8.4 Hz, Ar-H); 4.09 (t, 2H, J= 6.2 Hz, O-CH2); 3.64 (sa, 1H, BioHio-Ctf); 2.61 (t, 2H, J= 6.2 Hz, CH2-C); 2.47 (s, 3H, Ar-CH3); 2.74-1.62 (m, 10H, BioHio).

[0120] 13C-NMR 8 (150MHz, CDCh): 145.8 (Cq); 132.3 (Cq); 130.3 (2 x CH); 128.0 (2 x CH); 71.2 (Cq); 66.9 (CH2); 60.4 (CH); 36.9 (CH2); 21.8 (CH3).

[0121] UB-NMR 8 (192.5 MHz, CDCh): -2.77; -5.99; -10.22; -12.32; -13.46.

[0122] IR: 3058 cm'1(weak intensity, C-H stretching); 2604 cm'1and 2575 cm'1(medium intensity, B-H stretching o-carboranes); 1173 cm'1(strong intensity, C-0 stretching). m.p. = 106-110°C

[0123] Synthesis of 1-C-ortho-carboranylethanazide (15) l-C-ortho-carboranyl-2-(4-toluenesulfonate)ethane (14) (0.102 g, 0.30 mmoles, 1 equ.) is added to an 8 ml vial with a magnetic stir bar previously flamed under N2and is kept under vacuum for a few minutes. The vial is heated to 30°C and 1 ml of anhydrous DMF and NaN3(0.072 g, 1.20 mmoles, 4 equ.) are added. The reaction mixture is left to react for 2 hours. The conversion is monitored with TLC (EP:AcOEt 90: 10). The DMF is evaporated at reduced pressure obtaining a white solid. The raw product is purified by means of a chromatographic column (stationary phase 10 g of SiO2deactivated with 1% Et3N; eluent EP:DCM 80:20; Rf = 0.31). 1-C-ortho-carboranylethanazide (15) (0.051 g, 0.24 mmoles, 80%) is obtained as a transparent oil

[0012] , 'H-NMR 8 (600MHz, CDCh): 3.74 (sa, 1H, BioHio-CH); 3.47 (t, 2H, J = 6.8 Hz, CH2-N3); 2.46 (t, 2H, J= 6.9 Hz, C / A-C-BioHio); 2.57-1.76 (m, 10H, BioHio). °C-NMR 8 (150MHz, CDCh): 72.2 (Cq); 60.8 (CH); 49.6 (CH2); 36.8 (CH2).UB-NMR 8 (192.5 MHz, CDCh): -2.93; -6.15; -10.25; -12.30; -13.12; -13.77.

[0124] IR: 3066 and 2933 cm'1(weak intensity, C-H stretching); 2575 cm'1(strong intensity, B-H stretching o-carboranes); 2094 cm'1(strong intensity, N=N=N stretching); 1265 cm'1(medium intensity, C-0 stretching). Huisgen reaction: synthesis of ortho-carborane (11)

[0125] 1 equ. of 1-C-ortho-carboranylethanazide (15) (55 mg, 0.26 mmoles) is added, under N2, to an 8 ml vial with a magnetic stir bar previously flamed under vacuum, and left under a flow of N2 for a few minutes. (E)-N-methyl-4-(4-(2-(2- (2-(prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline (10) (103 mg, 0.26 mmoles, 1 equ.), Cu(OAc)2 (47 mg, 0.26 mmoles, 1 equ.) and sodium ascorbate (52 mg, 0.26 mmoles, 1 equ. ) are subsequently added, again under N2. the mixture is degassed for 10 minutes and 2.5 ml of anhydrous THF is then added. The solution is stirred at room temperature for 6 hours. The conversion is then monitored with TLC (EP:AcOEt 50:50). The solvent is evaporated at reduced pressure obtaining a water-green colored raw product. The raw product is purified by means of a chromatographic column (stationary phase 15 g of SiO2deactivated with 1% Et3N; eluent AcOEt:EP 80:20; Rf = 0.25). Ortho-carborane (11) (141 mg, 0.23 mmoles) is obtained as a yellow-orange waxy solid, with a yield of 89%

[0013] .

[0126] 'H-NMR 8 (600MHz, CDCh): 7.52 (s, 1H, C=CH-N); 7.35 (dm, 2H, J = 8.8 Hz, Ar-H); 7.31 (dm, 2H, J = 8.4 Hz, Ar-H); 6.89-6.79 (m, 4H, Ar-H e Ar-CH=CH- Ar); 6.56 (dm, 2H, J= 8.2 Hz, Ar-H); 4.64 (s, 2H, O-CH2-C=) 4.33 (m, 2H, N- CH2) 4.10 (m, 2H, Ar-O-CH2); 3.83 (m, 2H, O-CH2) 3.71 (m, 2H, O-CH2) 3.68- 3.64 (m, 7H, O-CH2-CH2-O e CH-B10H10); 2.83 (s, 3H, NH-CH3); 2.82-2.79 (m, 2H, e ( C-BioHio); 2.75-1.60 (m, 10H, B10H10).

[0127] °C-NMR 8 (150MHz, CDCh): 157.9 (Cq); 148.9 (Cq); 145.7 (Cq); 131.3 (Cq); 127.6 (CH); 127.2 (2 x CH); 127.1 (2 x CH); 126.9 (Cq); 123.9 (2 x CH); 123.3 (2 x CH); 115.0 (CH); 112.6 (CH); 71.4 (Cq); 70.9 (CH2); 70.68 (CH2); 70.66 (CH2); 69.9 (CH2); 69.8 (CH2); 67.7 (CH2); 64.6 (CH2); 61.9 (CH); 48.4 (CH2); 37.0 (CH2); 30.8 (CH3).

[0128] UB-NMR 8 (192.5 MHz, CDCh): -3.08; -6.05; -10.05; -13.09.

[0129] IR: 3389 cm'1(weak intensity, N-H stretching); 3042 and 2920 cm'1(weak and medium intensity, C-H stretching); 2586 cm'1(average intensity, B-H stretching o-carboranes); 1607 cm'1(strong intensity, C=C stretching); 1246 and 1093 cm'1 (strong intensity, C-0 stretching and C-N stretching); 827 cm-1 (strong intensity, C-H bending para-substituted aromatic ring).

[0130] Synthisis of Phoenix (21)

[0131] The synthesis scheme of the compound Phoenix (21) is illustrated in the following scheme:

[0132] 2,6-Bis((E)-3,4-bis((tetrahydro-2H-pyran-2-yl)oxy) _ benzylidene)-4-hydroxy- cyclohexan-l-one (18) 4-hydroxycyclohexan-l-one (16)

[0014] (0.034 g, 3.0 mmoles) and 3,4- bis((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (17) (2.08 g, 6.0 mmoles, 2.0 equ.)

[0015] in 60 ml of MeOH are dissolved in a 100 ml flask. The solution is heated to 50°C and LiOH.EEO (0.39 g, 9.0 mmoles, 3.0 equ.) is subsequently added. The reaction is kept under stirring at 50°C for 24 hours under an N2 atmosphere, it is then cooled and the MeOH evaporated under reduced pressure. The residue is extracted with diethyl ether (5 x 50 ml) after adding 75 ml of deionized water. The organic phases are then washed with brine (1x50 ml) and dried on Na2SO4. The crude oil obtained after evaporation of the volatile , , mmoles, 2.0 eq.) and the reaction mixture is left under stirring for 3.5 hours at room temperature. 500 pL of deionized water are added in order to destroy the excess base, followed by anhydrous Na2SO4. After stirring the solution vigorously for 10 minutes, the volatiles are removed under reduced pressure. The raw product is purified by means of column chromatography using EPZEE 2: 1 as the eluent mixture. 2,6-bis((E)-3,4-bis ((tetrahydro-2H-pyran-2-yl)oxy)benzylidene)-4-(prop- 2-in-l-yloxy) cyclohexan-l-one is obtained (19), a bright yellow spongy solid, as a mixture of stereoisomers (0.39 g, 0.53 mmoles, 53%).

[0133] 1H NMR(600 MHz, CDCl3, Me4Si) δ: 7.80 (sa, 2H, 2 x C=CH), 7.30-7.28 (m, 2H, 2 x Ar-H), 7.17-7.15 (m, 2H, 2 x Ar-H), 7.12-7.10 (m, 2H, 2 x Ar-H), 5.51 (sa, 1H, O-C7 / -O), 5.49 (sa, 1H, O-CH -O), 5.44 (sa, 1H, O-CH -O), 5.42 (sa, 1H, O- CH -O), 4.09-4.07 (m, 1H, CH -OH), 4.04-3.93 (m, 2H, CH2-O), 3.98-3.91 (m, 2H, CH2-O), 3.64-3.60 (m, 6H, 3 x CH2-O), 3.24-3.18 (m, 2H, 2 x CHaH-O), 3.07- 3.00 (m, 2H, 2 x CHaHb-O), 2.35-2.33 (m, 1H, C=CH), 2.06-1.85 (m, 12H, CH2- CH2-CH2), 1.75-1.60 (m, 12H, CH2-CH2-CH2).

[0134] °C{ lH}NMR(150 MHZ, CDCl3, Me4Si) 8: 188.7 (Cq), 148.5 (Cq), 148.3 (Cq), 147.1 (Cq), 147.1 (Cq), 146.9 (Cq), 146.9 (Cq), 138.9 (CH), 138.8 (CH), 131.0 (Cq), 131.0 (Cq), 130.9 (Cq), 130.2 (Cq), 130.0 (Cq), 125.8 (CH), 125.7 (CH), 125.6 (CH), 125.5 (CH), 121.4 (CH), 121.1 (CH), 121.02 (CH), 117.7 (CH),

[0135] 117.4 (CH), 98.1 (CH), 98.1 (CH), 97.7 (CH), 97.6 (CH), 97.4 (CH), 97.4 (CH), 97.0 CH 0, 97.0 (CH), 79.7 (Cq), 74.6 (CH), 71.8 (CH), 71.7 (CH), 71.6 (CH), 62.2 (CH2), 62.1 (CH2), 62.0 (CH2), 62.0 (CH2), 61.9 (CH2), 55.6 (CH2), 33.5 (CH2), 33.5 (CH2), 33.4 (CH2), 30.5 (CH2), 30.4 (CH2), 30.4 (CH2), 30.4 (CH2),

[0136] 25.4 (CH2), 25.3 (CH2), 18.8 (CH2), 18.7 (CH2), 18.7 (CH2), 18.5 (CH2).

[0137] Phoenix-OTHP (20)

[0138] 2,6-Z>z ((E)-3,4-Z>z ((tetrahydro-2H-pyran-2-yl)oxy)benzylidene)-4-(prop-2- in-l-yloxy) cyclohexan-l-one (19) (383.0 mg, 0.52 mmoles, 1.0 equ.) are suspended in a 20 ml Pirex© glass-walled vial together with 2-(C-o-carboranyl)- 1-azidoethane (15) (108.0 mg, 0.52 mmoles, 1.0 equ.) in 10 ml of an equimolar mixture of tetrahydrofuran and deionized water, under an inert atmosphere. The solution is treated with a flow of N2or Ar for 10 minutes in order to eliminate traces of O2, anhydrous Cui (100.0 mg, 0.52 mmoles, 1.0 equ.) is then added. The reaction is stirred vigorously for 24 hours, at 25°C under an inert atmosphere (N2or Ar). After removing the volatile substances under reduced pressure, the raw product is purified by chromatography on SiO2, using a 75:1 CH2Cl2 / MeOH eluent mixture. Phoenix-OTHP (20), a bright yellow spongy solid, is obtained as a mixture of stereoisomers (453.0 mg, 0.49 mmoles, 94% yield).

[0139] 'H NMR(600 MHz, CDCh, Me4Si) 8: 7.76-7.69 (bs, 2H, 2 x C=CH), 7.33-7.27 (m, 1H, triazole Ar-H), 7.25-7.20 (m, 2H, 2 x Ar-H , 7.14-7.09 (m, 2H, 2 x Ar-H), 7.08-7.01 (m, 2H, 2 x Ar-H), 5.50-5.44 (m, 2H, 2 x O-C / / -O), 5.42-5.39 (m, 1H, O-C / / -O), 5.37 (dt, 1H, J = 9.2, 3.2 Hz, O-C / / -O), 4.46-4.41 (m, 2H, triazole- CH2-O), 4.28-4.18 (m, 2H, triazole-CH2-CH2), 4.06-3.82 (m, 6H, 2 X O-CH2+ O- CH + carborane CH), 3.66-3.53 (m, 4H, 2 X Cf-CH), 3.15-3.01 (m, 4H, CH2-C - CH2), 2.70-2.61 (m, 2H tri azol e-CH2-(7A), 2.08-1.49 (m, 24H, 2 x CH2-CH2- CH2), 2.85-1.40 (bs, 10H, lO x BH).

[0140] °C{ lH}NMR(150 MHZ, CDCh, Me4Si) 8: 188.8 (Cq), 148.5 (Cq), 148.4 (Cq),

[0141] 148.3 (Cq), 148.2 (Cq), 147.1 (Cq), 147.0 (Cq), 146.9 (Cq), 146.9 (Cq), 145.6

[0142] (Cq), 145.6 (Cq), 138.6 (CH), 138.5 (CH), 130.9 (Cq), 130.9 (Cq), 130.8 (Cq),

[0143] 129.9 (Cq), 129.9 (Cq), 129.9 (Cq), 129.8 (Cq), 125.5 (CH), 125.3 (CH), 123.2

[0144] (CH), 123.1 (CH), 123.1 (CH), 121.4 (CH), 121.1 (CH), 121.0 (CH), 120.8 (CH),

[0145] 117.7 (CH), 117.6 (CH), 117.4 (CH), 117.4 (CH), 117.4 (CH), 98.1 (CH), 98.1 (CH), 97.7 (CH), 97.6 (CH), 97.4 (CH), 97.3 (CH), 97.0 (CH), 97.0 (CH), 72.2 (CH), 71.2 (Cq), 62.2 (CH2), 62.2 (CH2), 62.08 (CH2), 62.0 (CH2), 62.0 (CH2),

[0146] 62.0 (CH2), 61.9 (CH2), 61.9 (CH2), 61.9 (CH2), 48.3 (CH2), 36.8 (CH2), 36.8

[0147] (CH2), 33.4 (CH2), 33.3 (CH2), 30.4 (CH2), 30.4 (CH2), 30.3 (CH2), 30.3 (CH2),

[0148] 25.3 (CH2), 25.2 (CH2), 18.8 (CH2), 18.8 (CH2), 18.7 (CH2), 18.7 (CH2), 18.6

[0149] (CH2), 18.5 (CH2).

[0150] 11B NMR (192.5 Hz, CDCh, Me4Si) δ: -3.07 (bs, IB), -6.02 (bs, IB), -10.10 (bs, 2B), -13.09 (bs, 6B).

[0151] Phoenix (21)

[0152] Phoenix-OTHP (20) (450.0 mg, 0.48 mmoles, 1.0 equ) is dissolved in CHCh in a 100 ml flask. Amberlyst 15 (45.0 mg, 10% w / w) is then added in a single portion. The solution is left under vigorous stirring at 25°C until completion (as confirmed by ESI-MS analysis of the reaction mixture). MeOH or acetone are added until the product is completely dissolved, the solution is filtered to eliminate the Amberlyst 15 resin and the volatile substances removed under reduced pressure. The crude oil thus obtained is mixed with CH2Q2, subjected to centrifugation or filtration, allowing Phoenix (21), (230.0 mg, 0.40 mmoles, 83%) to be recovered as an ochre solid tending towards light orange. Alternatively, the product can be obtained through flash chromatography on SiO2, using pentane / AcOEt 1 : 1, 1% HCO2H as eluent..

[0153] Melting point: decomposition of the product at 103 °C

[0154] 'H NMR(600 MHz, acetone-d6 , Me4Si) δ: 8.21 (sa, 4H, 4 x Ar-OH), 7.78 (s, 1H, triazole Ar-H), 7.49 (s, 2H, 2 x C=CH), 6.96 (s, 2H, 2 x Ar-H , 6.83 (d, J = 8.2 Hz, 2H, 2 x Ar-H), 6.78-6.77 (d, J = 8.2 Hz, 2H, 2 x Ar-H), 4.66 (sa, 1H, carborane CH), 4.45-4.43 (m, 2H, N-CH2), 4.41 (s, 2H, O-CH2), 3.88-3.83 (m, 1H, O-CH), 3.11-2.93 (m, 4H, CH2-CH-CH2), 2.92-2.84 (m, 2H, N-CH2-C / / 2), 2.56-1.41 (sa, 10, lO x BH).

[0155] °C{ lH}NMR(150 MHZ, aceton e-d6 , Me4Si) 8: 188.3 (Cq), 147.2 (Cq), 145.8 (Cq), 145.7 (Cq), 138.4 (2 x CH), 131.3 (Cq), 128.9 (Cq), 124.6 (CH), 124.5 (2 x CH), 118.1 (2 x CH), 116.3 (CH), 73.6 (Cq), 72.6 (CH), 63.7 (CH), 61.8 (CH2), 49.0 (CH2), 37.4 (CH2), 34.1 (2 x CH2).

[0156] UB NMR (192.5 Hz, CDCl3, Me4Si) 8: -3.67 (sa, IB), -6.51 (sa, IB), -10.46 (sa, 2B), -12.67 (sa, 4B), -13.90 (sa, 2B).

[0157] Synthesis of BPiB (24)

[0158] The synthesis of the compound BPiB (24) is illustrated in the following scheme:

[0159] Alkylation

[0160] 4-(6- -2-vl)-N-(prop-2-in-l-yl) aniline (23)

[0161] 4-(6-methoxybenzo[d]thiazol-2-yl)aniline (22) (0.60 g, 2.2 mmoles, 4.9 equ.) is dissolved in 2.0 ml of anhydrous DMF in a 20 ml Pirex© glass-walled vial, previously dried under vacuum, K2CO3 (152.0 mg, 1.1 mmoles, 2.4 equ.) is added in a single portion under vigorous stirring. After 5 minutes, propargyl bromide (50.0 pL, 0.45 mmoles, 1.0 equ., 80% sol in toluene w / w) is added via syringe, the vial is then closed, also sealing it with parafilm and the reaction mixture is stirred at 25°C for 18 hours. The volatile substances are removed under reduced pressure and the reaction raw product is purified by means of flash chromatography on SiCh, eluent EP / AcOEt 7:3 (r.f. 0.37). 4-(6- methoxybenzo[d]thiazol-2-yl)-N-(prop-2-in-l-yl) aniline (23) is obtained as a yellowish powder (132.0 mg, 0.42 mmoles, quantitative yield ).

[0162] Melting point: 171-173°C

[0163] 'H NMR(600 MHz, CDCh, Me4Si) 8: 7.92-7.89 (m, 2H, Ar-H), 7.88 (d, 1H, J =

[0164] 8.9 Hz, Ar-H), 7.33 (d, 1H, J= 2.6 Hz, Ar-H), 7.05 (dd, 1H, J= 8.9, 2.6 Hz, 1H), 6.75-6.70 (m, 2H, Ar-H), 4.23 (bs, 1H, N / Z), 4.01 (d, 2H, J = 2.4 Hz, NH-C / A) 3.88 (s, 3H, OCH3), 2.26 (t, 1H, J= 2.4 Hz, C=CH).

[0165] °C{ lH}NMR(150 MHZ, CDCh, Me4Si) 8: 166.3 (Cq), 157.4 (Cq), 149.0 (Cq),

[0166] 135.9 (Cq), 128.9 (2 x CH), 124.1 (Cq), 123.1 (CH), 115.3 (CH), 113.3 (2 x CH), 104.4 (CH), 80.3 (Cq), 71.9 (CH), 56.0 (CH2), 33.4 (CH3). IR vmax (neat) / cm : 3268 (C=CH), 3230 (NH), 1599, 1461, 1274, 842.

[0167] BPiB(24)

[0168] Anhydrous Cu(OAc)2 (91.0 mg, 0.50 mmoles, 1.0 equ.) and sodium ascorbate (99.0 mg, 0.50 mmoles, 1.0 equ.) are inserted in a vial. The vial is put under reduced pressure to eliminate traces of O2 and is subsequently saturated with N2. 5 ml of anhydrous THF are then added and the reaction is stirred vigorously at 25°C for 24 hours. The reaction mixture is filtered on a small layer of Celite after dilution with 10 ml of EtOAc. The volatile substances are then eliminated under reduced pressure.

[0169] The reaction raw product is purified on SiCh flash, eluent EP / AcOEt 1 : 1 (r.f. 0.37), BPiB (24) is obtained, as a yellowish powder, with a yield of 95%.

[0170] Melting point: decomposition at 208°C

[0171] 'H NMR(600 MHz, CDCh, Me4Si) 8: 7.89-7.84 (m, 3H, Ar-H), 7.43 (s, 1H, triazole Ar-H , 7.30 (d, 1H, J = 2.5 Hz, Ar-H), 7.05 (dd, 1H, J = 8.9, 2.5 Hz, Ar- H), 6.69 (dm, 2H, J = 8.7 Hz, Ar-H), 4.66 (bs, 1H, N / Z), 4.50 (s, 2H, NHC / A), 4.49-4.36 (m, 2H, N-C / Z2), 3.88 (s, 3H, OCH3), 3.72 (bs, 1H, carborane CH), 3.00-2.83 (m, 2H, N-CH2-C / / 2), 2.82-1.64 (bs, 10H, Btf)

[0172] °C{ lH}NMR(150 MHZ, CDCh, Me4Si) 8: 166.2 (Cq), 157.4 (Cq), 149.5 (Cq), 148.6 (Cq), 146.2 (Cq), 135.9 (Cq), 129.0 (2 x CH), 123.7 (Cq), 123.0 (CH), 122.2 (CH), 115.3 (CH), 113.0 (2 x CH), 104.5 (CH), 71.2 (Cq), 61.8 (CH), 55.9 (CH3), 48.6 (CH2), 39.5 (CH2), 37.0 (CH2).

[0173] UB NMR (192.5 Hz, CDCh, Me4Si) 8: -2.95 (bs, IB), -5.95 (bs, IB), -9.96 (bs, 2B), -12.91 (bs, 2B), -13.74 (bs, 2B).

[0174] IR vmax (neat) / cm4: 3384 (NH), 2586 (BH), 1604, 1460, 822.

[0175] EXAMPLE 2: Preparation of nanoparticles containing CENI agents i) Poly-lactic-co-glycolic acid (PLGA) nanoparticles

[0176] Two different protocols were used for the preparation of PLGA nanoparticles both based on the formation of an oil / water emulsion.

[0177] Method 1 : The organic phase was prepared by dissolving 12.5 mg of PLGA Resomer® RG 502 H, 2.2 mg of DSPE-PEG(2000)methoxy and 4 mg of Phoenix (21) in 0.5 ml of chloroform-methanol 3: 1 (v / v). The aqueous phase consists of 3 ml of a 3% (w / v) aqueous solution of Mowiol 4-88. The organic PLGA solution was mixed with the PVA solution dropwise and immediately sonicated at 4 °C, 4 times, for 1 minute, at 100% sonication power. The organic phase was removed by evaporation in a 500 mL round glass flask for 2 hours.

[0178] After evaporation, the drug not incorporated within the nanoparticle was removed by dialysis (membrane cut-off 14,000 Da) at 4°C in 2 L of isotonic NaCl / Hepes buffer (HBS). The excess PVA was removed by washing the solution of NPs with a vivaspin 20 filter (Sartorius AG, Goettingen, Germany, cut-off of 1 x 106Da) and, at the end of the washing step, a final volume was reached of 3 ml for all nanoparticle suspensions considered. Following this protocol, PLGA nanoparticles having average dimensions of 140-150 nm, PDI 0.14, were obtained. The internalization of Phoenix (21) was assessed by means of ICP-MS: with a yield of 83%.

[0179] Method 2: In the second method, PLGA nanoparticles having average dimensions of 80-90 nm, PDI 0.17, were prepared by an emulsion-evaporation method, modified with some elements typical of the nanoprecipitation method. For standard nanoparticles, 25 mg of PLGA (50:50 L:G, Mw 7,000-17,000) and 4 mg of Phoenix (21) were dissolved in 2.5 mL of ethyl acetate. 75 uL of a solution of l,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine Rhodamine B sulfonyl) (ammonium salt) in chloroform was then added to the organic phase. The organic phase was added dropwise (25uL / sec, using a 1.25 ml disposable syringe for dispensers (Savatec)), under vigorous magnetic stirring (1030 rpm), to the PVA solution (MOWIOL 4-88, 3% w / v, 5 ml). The pre-emulsion was stirred for 1 minute and then homogenized by sonication with a SONOPULS HD2070 ultrasonic homogenizer (Bandelin) with an MS72 microtip at 70% power for 5 minutes in an ice bath. The organic phase was finally evaporated by means of a rotavapor and left under vacuum for 2 hours. The nanoparticle suspension obtained was dialyzed in 1 litre of dialysis buffer overnight and, after changing the buffer, for a further 6 hours. The nanoparticles were then washed 3 times in dialysis buffer and concentrated by centrifugation using vivaspin filters (Vivaspin 20 MWCO 100000). The nanoparticles were centrifuged at 3,000 rpm for 5 minutes to remove larger aggregates and collected to be characterized by DLS (Malvern Zetasizer Nano-ZS). The drug internalization was assessed by ICP-MS: from 50 to 70% of the drug initially dissolved was found. ii) Preparation of adducts of CENI agents with poly-cyclodextrins

[0180] In order to form the inclusion complex, the stock solution of the compound Phoenix (21) was prepared in absolute ethanol and the P-cyclodextrin polymer in 0.9% NaCl. For each mouse, they were mixed and sonicated in an ultrasonic bath for 5' immediately before intravenous administration to obtain a stoichiometric ratio of Phoenix (21) and P-cyclodextrin monomer in the Phoenix / p-CD complexes of 1 :8 in approximately 0.25 ml of saline solution containing 10% ethanol. Each mouse received a dose of 45 mg / kg of Phoenix corresponding to approximately 8 ppm of boron. After 1 hour, the mice were euthanized and perfused with 40 ml of PBS. Liver and brain fragments were collected to determine the boron content by means of ICP-MS. iii) The Phoenix CENI agent (21) was charged into the apoferritin cavity according to the following procedure. Dissociation of the apoferritin into its subunits was effected by lowering the pH of the protein solution (1 x 10-5mol / L) to pH 2 with 1 M HC1 and maintaining this pH for approximately 15 minutes. 5 pL of Phoenix solution in ethanol (200 mg / mL) was subsequently added to each milliliter of apoferritin solution. The pH was then adjusted to 7.4 using IM NaOH. The solution obtained was stirred at room temperature for 2 hours and then, after centrifugation, purified by gel filtration (superdex G25 column, Amersham) and dialysis. At the end of this process, the concentrations of the protein (using the Bradford method, standard BSA) and boron were measured. The concentration of B was determined using inductively coupled plasma mass spectrometry (ICP-MS; element-2; Thermo-Finnigan, Rodano (MI), Italy). Digestion of the samples was effected with concentrated HNO3 (70%, 2 ml) under microwave heating (ETHOS UP Milestone, Bergamo, Italy).

[0181] EXAMPLE 3 : Determination of the affinity for Af fibrils In order to verify the capacity of the CENI agents according to the invention to act as selective Ap binders, preliminary in vitro experiments were performed using preformed Ap fibrils.

[0182] The affinity of the CENI agents indicated in Figure 4 for Ap[l-42] fibrils (prepared in a phosphate buffer) was determined using a fluorescent bioassay based on the detection of the intrinsic fluorescence of thioflavin T (ThT). ThT is a dye commonly used for monitoring the formation of amyloid fibrils in vitro. When binding to amyloid fibrils, ThT gives a strong fluorescence signal at approximately 475-485 nm when excited at 450 nm

[0016] ,

[0183] The binding of CENI agents cannot be directly observed, as, following binding with Ap[l-42] fibrils, they do not generate a characteristic fluorescence emission as is the case for ThT. The affinity was therefore determined using a competition assay employing the ThT probe, measuring the emission fluorescence.

[0184] Competition assays were effected using a fixed concentration of Ap[l -42] (0.2 pM) and ThT (100 nM) and a variable concentration of competitor binder (10 to 400 nM). The reactions were effected in a phosphate buffer with 5% ethanol for 3 hours at 20°C, stirring at 400 rpm (Figure 5).

[0185] The data were analyzed with origin. lab software to determine the IC50. Finally, the Ki values were obtained from the Cheng-Prusoff equation

[0017] ,

[0186] Ki = IC50 / (l +([L] / Kd)) (Equation 1) wherein [L] is the concentration of ThT (100 nM) and Kd (8.8 pM) used in the assay.

[0187] Table 1 indicates the Ki values obtained for the preferred compounds according to the invention and by competition assay, measuring the fluorescence emission of ThT at 476 nm.

[0188] Table 1

[0189] From these results it can be seen that:

[0190] - the Pittsburgh compounds and its carboranic derivative BPiB show similar affinities. The entire Pittsburgh molecule is required for an efficient binding to the fibrils;

[0191] - the compounds with a greater affinity are those inspired by curcumin, such as Phoenix (21). The dissociation constant (Ki) is similar to those indicated in literature for Congo red (within the range 0.1-1.5 pM [18,19],

[0192] All of the CENI compounds showed a higher or similar affinity to that of ThT and Congo red (CR) dyes for beta-amyloid fibrils. It is therefore impossible to use ThT and CR as an indicator of the aggregation / disaggregation of A|3 fibrils due to the risk of overestimating the disaggregating effect due to the competition of ThT with the binder itself.

[0193] EXAMPLE 4: Preliminary biodistribution tests

[0194] Preliminary in vivo experiments were effected to study the biodistribution of PLGA nanoparticles incorporating the compounds of the invention.

[0195] The first group (n=2) was treated with 25 mg / kg of Phoenix incorporated in PLGA nanoparticles intravenously (i.v.) (4.46 ppm of boron); the second group (n=2) with 25 mg / kg of Phoenix incorporated within PLGA nanoparticles by subcutaneous injection into the cervical lymph node region and the third group (n=2) received an equal volume of saline solution (vehicle) . After 24 hours, the mice were sacrificed and perfused with 40 ml of PBS. Liver and brain were collected to determine the boron content by means of ICP-MS.

[0196] Figure 6 shows the ICP-MS analysis of the boron content effected ex vivo 24 hours after administration of PLGA-Phoenix in the brain of mice treated with vehicle and PLGA-Phoenix (SQ = subcutaneous injection; IV = intravenous injection).

[0197] Table 2 indicates the ppm of boron found in the liver and brain after administration of PLGA-Phoenix. Table 2

[0198] The quantities of boron measured within the brain of the mice treated are significantly greater than in the control mice. The two different types of administration (SQ or IV) however do not show significant differences.

[0199] EXAMPLE 5: Pilot irradiation at the TRIG A Mark II reactor of the University of Pavia

[0200] The compound called Phoenix (21) was selected to perform the first pilot irradiation experiments. Phoenix (21) is in fact the compound that has shown the greatest affinity for the fibrillar aggregates of beta amyloid (see the results of Example 3).

[0201] For these irradiation experiments, derivatives containing carborane enriched in10B were used. Natural B, in fact, contains only about 20% of the10B isotope, the only one active in the neutron capture reaction. Consequently, in order to increase the probability of generating an effective reaction with neutrons, it is essential to use compounds enriched with more than 90% of the10B isotope.

[0202] Furthermore, as determined by the titration described in Table 1, the compound Phoenix (21) showed excellent affinity for beta-amyloid. From Ki it can be calculated that over 95% of Phoenix is bound to beta-amyloid when this is incubated in a 1 : 1 molar ratio with the oligomers (for 5 days at 37°C to form Ap fibrils). Consequently, the estimated pg / g (ppm) of boron bound to the aggregates under these conditions are approximately 5, calculated by employing the total volume of the Ap-fibril sample as the denominator.

[0203] In order to allow complete binding and penetration inside the AP-fibrils, the compound called Phoenix (50 pM) was incubated with the AP-fibrils for 24 hours at 37°C before neutron irradiation using the same concentration of oligomers (50 pM) dissolved in phosphate buffer. The preliminary results relate to the neutron irradiation of two different samples, for a period of one hour using a reactor power of 250 kW. The experiment was repeated three times and the results compared with what was obtained on similar non-irradiated samples.

[0204] The irradiated samples were:

[0205] A) Ap CTRL fibrils

[0206] B) Ap fibrils + Phoenix 50 pM

[0207] At the end of the experiment the disaggregation of the fibrils was evaluated using Field Emission Scanning Electron Microscopy (FESEM) as illustrated in Figure 7.

[0208] Figure 7 clearly shows a significant disaggregation effect, following irradiation, obtained only in the presence of the compound Phoenix (21). Neutrons alone cannot generate enough energy to induce disaggregation.

[0209] Figure 8 shows the optical density measurements of the FESEM images multiplied by the area covered. In particular, a % decrease can be appreciated in the aggregates of Ap fibrils irradiated for 1 hour at 250 kW in the presence of Phoenix or not irradiated.

[0210] This important preliminary result is the first demonstration that a compound containing boron and having a high affinity for amyloid beta fibrils can induce their disaggregation. In the future, different irradiation conditions will be tested in order to reduce the reactor power and irradiation time.

[0211] EXAMPLE 6: Post-irradiation analysis of A I fibril samples

[0212] The peptide Api-42 was incubated with CENI compounds (Chimera, Phoenix and BPiB) at a 1 : 1 concentration. In order to allow complete binding and penetration into the AP-fibrils, the CENI compounds were incubated with the AP- fibrils for 24 hours at 37°C before neutron irradiation using the same concentration of oligomers (50 pM) dissolved in phosphate buffer. Non-irradiated Ap fibril samples, incubated under the same conditions described above with or without CENI compounds, are used as control samples.

[0213] As a further control, irradiated or non-irradiated Ap fibrils were analyzed with the ThT assay, only in the absence of CENI compounds that can produce a decrease in fluorescence by competition at the same ThT binding sites. As Figure 9 shows, no significant variation in the fluorescence is observed between the samples subjected or not subjected to irradiation, thus confirming that neutrons alone are not capable of triggering any disaggregation process.

[0214] In this study, various irradiation conditions (in terms of reactor power and irradiation time) were explored to approach the clinical translation of the treatment.

[0215] Two powers (250 and 30 kW) and two irradiation times (1 hour and 15') are therefore used. 1 hour at 250 kW was selected as the reference condition and was repeated in several irradiation sessions to verify the reproducibility of the experiments. The fibrils prepared with commercial Api-42 peptides ,in fact, have a well-known high intrinsic variability due to a partial oligomerization of the peptide that takes place even during storage at -20°C. This influences the aggregation, maturation and therefore the aggregation rate of the fibrils.

[0216] Disaggregation analysis of all irradiated and non-irradiated samples, including Ap controls, was effected by FESEM electron microscopy. After the irradiation experiment in order to remove excess salts, the samples are diluted and centrifuged and after removal of the supernatant, the pellet is resuspended and 10 pL of this solution is spread onto a cover glass coated with a layer of gold . In order to evaluate the morphology of the fibrils, images of the samples were acquired with a Tescan FEG-SEM S9000. Measurements were effected with a Schotty emitter (0.7 nm resolution at 15 keV and 1.4 nm at 1 keV), the probe set at 100 pA, and the electron beam energy at 5 keV. The analysis was effected with an in-beam SE detector. The microanalysis was carried out with OXFORD - Detector Ultim Max - AZTEC Software.

[0217] The images acquired were analyzed by means of Imaged software. Prior to analysis, the black and white values are reversed to display the Ap fibrils in white and the background in black. A manual threshold is then applied to each image to segment the Ap fibrils from the background. The selected area is then analyzed by the software to extrapolate three parameters: the area (expressed in square pixels), the average grey value (the sum of the grey values of all the pixels in the selection divided by the number of pixels) and the density integrated (the product of area and mean grey value). In order to obtain a semi-quantitative evaluation of the quantity of fibrils present in the sample, for each experimental condition, 15 images were analyzed with the protocol described above (Figure 10). Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Inc., San Diego, CA, USA). The data are presented as mean % ± SD, unless otherwise indicated. One-way analysis of the variance (ANOVA) was used for verifying the presence of statistically significant differences between the parameter measurements of different groups of Ap samples. For all tests, a P value of < 0.05 is considered statistically significant.

[0218] 1 hour irradiation Reactor power: 250 kW

[0219] Figure 11 shows the residual fibrils present in the different samples irradiated at 250 kW for 1 hour. The results are the average of five independent experiments in five different irradiation sessions. The optical density was normalized to the value measured on the non-irradiated Ap CTRL sample, which is set to 100. Lower optical densities suggest a greater disaggregation effect.

[0220] Figure 11 shows a significant disaggregation of Ap in samples irradiated in the presence of Phoenix (21). From these results it can be concluded that neutrons alone are unable to generate sufficient energy for inducing disaggregation. Although with a low reproducibility, only Chimera is capable of inducing a partial disaggregation of Ap fibrils without the synergistic effect of neutrons.

[0221] It is interesting to note that, by repeating the same experiment with nonmature proto-fibrils (400 rpm condition), which show a low binding to ThT (and therefore presumably also a low binding to CENI compounds), no disaggregation effect is observed (Figure 12). This may confirm the hypothesis that, in order to be effective, boron-containing compounds must be bound to protein aggregates.

[0222] Positive results are also obtained by reducing the irradiation time to 15 minutes with both a reactor power of 250 kW and 30 kW (Figure 13).

[0223] On analyzing the results obtained, it can be concluded that Phoenix (21) is the most effective CENI compound as it is capable of inducing the "in vitro" disaggregation of the P-amyloid fibril triggered by neutron capture. Among the CENI agents, Chimera is the only compound capable of inducing P-amiloid disaggegation on its own.

[0224] These results are also confirmed by further tests effected using the Surface Plasmon Resonance (SPR) technique. Solutions containing Api-42 fibrils, incubated or not with CENI agents, irradiated or not, are prepared for SPR analysis. The resulting plots (time trend of the SPR signal in resonance units, RU) are analyzed in order to determine the fast-dissociating and slow-dissociating components of the SPR binding signal, identifying monomers and oligomers, respectively. In particular, the monomeric component is the difference between the maximum binding signal at the end of the association phase and the signal measured at the end of the dissociation phase. The following graphs show oligomer-dependent Ap signals.

[0225] In Figure 14, an increase in oligomers is observed in the Phoenix+irradiation condition compared to the Phoenix condition alone. According to the results obtained during the characterization of the SPR assay, the increase in the SPR signal is suggestive of an induced fragmentation of Api-42 fibrils. The effect of Phoenix+irradiation is particularly marked in the irradiation sessions 15' x 30kW and 15' x 250kW.

[0226] The experiment suggests that Phoenix (21) alone or irradiation alone have no effect, but only their combination increases the SPR signal dependent on the formation of the oligomers that are formed following fragmentation of amyloid beta.

[0227] BIBLIOGRAPHY

[0228] [1] Bhushan et al, Ann Biotechnol 2018 1(1): 1002.

[0229] [2] Ceyzeriat et al, J Alzheimers Dis. 2020;74(2):411-419.

[0230] [3] F. Pacchiano,et al. J . Med. Chem. 54(11) (2011) 3768-3778.

[0231] [4] Bucher, J.; Wurm, T.; Nalivela, K. S.; Rudolph, M.; Rominger, F.; Hashmi, A.

[0232] S. K. Cyclization of Gold Acetylides: Synthesis of Vinyl Sulfonates via Gold Vinylidene Complexes. Angew. Chem. Int. Ed. 2014, 53 (15), 3854-3858.

[0233] [5] Kang, J.; Young Lee, J.; Ta§, I.; More, K. N.; Kim, H.; Park, J.-H.; Chang, D - J. Radiosynthesis, Biological Evaluation and Preliminary MicroPET Study of 18F-Labeled 5-Resorcinolic Triazol one Derivative Based on Ganetespib Targeting HSP90. Bioorganic & Medicinal Chemistry Letters 2018, 28 (23-24), 3658-3664.

[0234] [6] Lottner, C.; Bart, K.-C.; Bernhardt, G.; Brunner, H. Soluble Tetraarylporphyrin-Platinum Conjugates as Cytotoxic and Phototoxic Antitumor Agents. J. Med. Chem. 2002, 45 (10), 2079-2089.

[0235] [7] Bao, L.-L. & Liu, Z.-Q. Tetrahydropyrrolization of Resveratrol and Other Stilbenes Improves Inhibitory Effects on DNA Oxidation. ChemMedChem 2016, 11 (15), 1617-1625.

[0236] [8] Liang, J.-H. et al.. Discovery of Efficient Stimulators for Adult Hippocampal Neurogenesis Based on Scaffolds in Dragon’s Blood. European Journal of Medicinal Chemistry 2017, 136, 382-392.

[0237] [9] Huang, Y. et al. Metal-Chelating Benzothiazole Multifunctional Compounds for the Modulation and64Cu PET Imaging of Ap Aggregation. Chem. Sci. 2020, 11 (30), 7789-7799.

[0238]

[0010] Knueppel, D. & Martin, S. F. Tandem Electrocyclic Ring Opening / Radical Cyclization: Application to the Total Synthesis of Cribrostatin 6. Tetrahedron 2011, 67 (51), 9765-9770.

[0011] Toppino, A. et al. High Yielding Preparation of Dicarba- Closo - Dodecaboranes Using a Silver(I) Mediated Dehydrogenative Alkyne-Insertion Reaction. Inorg. Chem. 2013, 52 (15), 8743-8749.

[0239]

[0012] Qiao, J. X. et al. Achieving Structural Diversity Using the Perpendicular Conformation of Alpha- Substituted Phenylcyclopropanes to Mimic the Bioactive Conformation of Ortho- Substituted Biphenyl P4 Moieties: Discovery of Novel, Highly Potent Inhibitors of Factor Xa. Bioorganic & Medicinal Chemistry Letters 2008, 18 (14), 4118-4123.

[0240]

[0013] Toppino, A. et al. A Carborane-Derivative “Click” Reaction under Heterogeneous Conditions for the Synthesis of a Promising Lipophilic MRI / GdBNCT Agent. Chem. Eur. J. 2013, 19 (2), 721-728.

[0241]

[0014] Azzi, E.; Alberti, D.; Parisotto, S.; Oppedisano, A.; Protti, N.; Altieri, S.; Geninatti-Crich, S.; Deagostino, A., Design, synthesis and preliminary in-vitro studies of novel boronated monocarbonyl analogues of Curcumin (BMAC) for antitumor and P-amiloyd disaggregation activity. Bioorg. Chem. 2019, 93, 103324.

[0242]

[0015] Witt, C. H., & Woerpel, K. A. (2022). Diastereoselective Alkylations of Chiral Tetrazolo[l,5-a]azepines via Heterob enzy lie Anion Intermediates, Org. Lett., 24(37), 6722-6727.

[0243]

[0016] M.R.H. Krebs et al. Journal of Structural Biology 149 (2005) 30-37.

[0244]

[0017] Cheng, Y., et al (1973) Biochem. Pharmacol. 22, 3099-3108.

[0245]

[0018] K. Yokoyama et al. Journal of Biophysical Chemistry 1 (2010) 153-163.

[0246]

[0019] M. Groenning J Chem Biol (2010) 3: 1-18.

Claims

CLAIMS1. Ccompounds having formula (I):R1-R2-X-R3-Z-R4 (I) wherein:X is a closo- or nido- ortho carborane;Ri, present only if R2 is different from a hydrogen atom, is a macrocycle selected from the group which consists of:- l,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA),155Gd-DOTA,157Gd-DOTA;- diethylenetriaminepentaacetic acid (DTP A),155Gd-DTPA,157Gd-DTPA;- 1,4,7- triazacyclononane-l,4,7-triacetic acid (NOTA),155Gd-NOTA,157Gd- NOTA;- tetraazacyclodidecane-BN, N', N", N'" tetra methylenephosphonate (DOPT),155Gd-DOTP,157Gd-DOTP;R2 is a hydrogen atom or, if Ri is present, it is a C2-C12 alkyl or heteroalkyl chain optionally comprising one or more functional groups selected from a triazole ring, amide group, urea or thiourea;R3 is an alkyl chain having the formula Cx-Y-Czwherein:Cxis a C2-C6 alkyl chain;Y is a triazole ring, or an amide group, urea or thioureaCz is a -(CH2)n- group, wherein n is an integer ranging from 2 to 6,-CH2NH-, -(CH20)m-, -(CH2CH2O)m-, -(CH2CH2O)mCH2- wherein m is an integer ranging from 1 to 3;Z is an oxygen, sulfur or NH group;R4 is selected from the group which consists of:wherein Q is -CH- or -N-; wherein Rs and Re, the same as or different from each other, are selected from the group which consists of:- an aromatic ring containing from one to three substituents having the following formula:wherein G, G’, G”, the same as or different from each other, can be selected from the group consisting of H, OH, Ci-Ce linear alkyloxy or halogen (F, I, Cl and Br);- an aromatic ring containing a heteroatom selected from the group consisting of: 2-pyridyl, 3-pyridyl or 4-pyridyl, benzoxazole, or benzothiazole or stilbene derivatives selected from the group consisting of:wherein the groups R7 and Rs, the same as or different from each other, are a Ci- C , linear alkyl group; stereoisomers thereof or pharmaceutically acceptable salts thereof with alkaline metals.

2. The compounds having formula (I) according to claim 1, wherein the closo- or nodo-ortho carborane contains10B ornB atoms.

3. The compound according to each of claims 1-2, wherein R4 comprises a monocarbonyl analogue of curcumin (MAC).

4. The compound according to claim 3, having formula (21):

5. The compound according to each of claims 1-2, wherein R4 comprises a benzothiazole derivative selected from the group consisting of:

6. The compound according to claim 5, having formula (24):• = CO = BH BPiB7. The compound according to each of claims 1-2, wherein R4 comprises a stilbene derivative selected from the group consisting of:wherein the groups R7 and Rs, the same as or different from each other, are a Ci-Ce linear alkyl group.

8. The compound according to claim 7, having formula (11):O = BH B-Florbetaben9. Compounds according to each of claims 1-8, for use in the medical field.

10. Compounds according to each of claims 1-8 for use in the treatment ofAlzheimer's disease.

11. Compounds according to claim 10, for use in the treatment of Alzheimer's disease by Capture-Enhanced Neutron Irradiation (CENI).

12. Compounds according to each of claims 1-8, when containing Gd, for use as probes in imaging methods, preferably MRI.

13. Pharmaceutical compositions comprising at least one of the compounds according to each of claims 1-8, as active ingredient together with one or more pharmacologically acceptable excipients and / or adjuvants.

14. A nanoformulation comprising: i) co-glycolic lactic acid (PLGA) polymer nanoparticles; ii) cyclodextrins in monomeric or polymeric form; or iii) apoferritin; in association with at least one of the compounds according to each of claims 1-8.

15. A pharmaceutical composition or nanoformulation according to claim 13 or 14, wherein said compound is selected from the compounds having formula (24), (11) or (21).

16. A process for the synthesis of the compound having formula (21) according to claim 4, comprising the following steps: i) Claisen-Schmidt condensation between 4-hydroxycyclohexan-l-one (16) and 3,4-bis((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (17) to obtain 2,6- Bis((E)-3,4-bis((tetrahydro-2H-pyran-2-yl)oxy)-benzyl-idene)-4- hydroxycyclohexan-l-one (18); ii) propargylation reaction of compound (18) with propargyl bromide to obtain 2,6-bis((E)-3,4-bis((tetrahydro-2H-pyran-2-yl)oxy) benzyl-idene)-4-( prop- 2 -in- 1 -yloxy)cyclohexan- 1 -one (19); iii) Huisgen reaction of compound (19) with 2-(C-o-carboranyl)-l -azidoethane to obtain compound (20); iv) deprotection of compound (20) in an acidic environment to obtain compound (21).

17. A process for the synthesis of the compound having formula (11) according to claim 6, comprising the following steps:(i) monopropargylation of tri ethylene glycol (2) with propargyl bromide (1) to obtain 2-(2-(2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethane- 1 -ol (3);(ii) tosylation of compound (3) to obtain 2-(2-(2-(prop-2-in-l- yloxy)ethoxy)ethoxy)ethyl 4-toluene sulfonate (4);(iii) Williamson etherification of 4-hydroxy benzaldehyde (5) to obtain 4-(2-(2- (2-(prop-2-in- 1 -yloxy)ethoxy)ethoxy)ethoxy)benzaldehyde (6);(iv) Horner-Wadsworth -Emmons reaction of compound (6) for the synthesis of stilbene (E)-l-nitro-4-(4-(2-(2-(2-(prop-2-in-l-yloxy)ethoxy)-ethoxy)ethoxy)- styryl)benzene (8);(v) reduction of the nitro group of compound (8) to obtain (E)-4-(4-(2-(2-(2- (prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline ( 9);(vi) reductive amination of compound (9) to obtain (E)-N-methyl-4-(4-(2-(2-(2- (prop-2-in-l-yloxy)ethoxy)ethoxy)ethoxy)styryl)aniline (10);(vii) Huisgen reaction of compound (10) with 1-C-ortho-carboranylethanazide to obtain compound (11).

18. A process for the synthesis of the compound having formula (24) according to claim 8, comprising the following steps: i) propargylation reaction of the compound 4-(6-methoxybenzo[d]thiazol-2- yl)aniline (22) by the addition of propargyl bromide to obtain 4-(6- methoxybenzo[d]thiazol-2-yl)-N-(prop-2-in-l-yl)aniline (23); ii) Huisgen reaction of the compound 4-(6-methoxybenzo[d]thiazol-2-yl)-N- (prop-2-in-l-yl)aniline (23) with 1-C-ortho-carboranilethanazide to obtain compound (24).

Citation Information

Patent Citations

  • Carborane hydroxamic acid matrix metalloproteinase agents for boron neutron capture therapy

    WO2020252439A1